相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
Renee de Leeuw et al.
CLINICAL CANCER RESEARCH (2015)
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
Daniel P. Petrylak et al.
LANCET ONCOLOGY (2015)
Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer
Eugene K. Cha et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
Mechanisms of Resistance to Cabazitaxel
George E. Duran et al.
MOLECULAR CANCER THERAPEUTICS (2015)
N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy
Sarah K. Martin et al.
MOLECULAR ONCOLOGY (2015)
Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
Maria Thadani-Mulero et al.
CANCER RESEARCH (2014)
A Randomised Phase II Trial Comparing Docetaxel Plus Prednisone with Docetaxel Plus Prednisone Plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer
Markus Porsch et al.
CHEMOTHERAPY (2014)
Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
Mercedes Marin-Aguilera et al.
MOLECULAR CANCER THERAPEUTICS (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ERG induces taxane resistance in castration-resistant prostate cancer
Giuseppe Galletti et al.
NATURE COMMUNICATIONS (2014)
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Ana M. Aparicio et al.
CLINICAL CANCER RESEARCH (2013)
Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer
Karim S. Fizazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
David I. Quinn et al.
LANCET ONCOLOGY (2013)
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
Ian F. Tannock et al.
LANCET ONCOLOGY (2013)
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
Pirkko-Liisa Kellokumpu-Lehtinen et al.
LANCET ONCOLOGY (2013)
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Gwenaelle Gravis et al.
LANCET ONCOLOGY (2013)
Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205
Martin Puhr et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
J. S. de Bono et al.
ANNALS OF ONCOLOGY (2012)
Expression of human ABCB5 confers resistance to taxanes and anthracyclines
Takaaki Kawanobe et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
The Role of IMiDs Alone or in Combination in Prostate Cancer
Chadi Nabhan et al.
CLINICAL GENITOURINARY CANCER (2012)
Phase II Trial of Weekly Ixabepilone in Men With Metastatic Castrate-Resistant Prostate Cancer (E3803): A Trial of the Eastern Cooperative Oncology Group
Glenn Liu et al.
CLINICAL GENITOURINARY CANCER (2012)
New Strategies Against Prostate Cancer – Pt(II)-Based Chemotherapy
C. S. Matos et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
William Kevin Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
A. Flechon et al.
ANNALS OF ONCOLOGY (2011)
Ixabepilone, Mitoxantrone, and Prednisone for Metastatic Castration-Resistant Prostate Cancer After Docetaxel-Based Therapy A Phase 2 Study of the Department of Defense Prostate Cancer Clinical Trials Consortium
Andrea L. Harzstark et al.
CANCER (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Chemotherapy Sensitivity Recovery of Prostate Cancer Cells by Functional Inhibition and Knock Down of Multidrug Resistance Proteins
Catherine Sanchez et al.
PROSTATE (2011)
Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials
M. M. Regan et al.
ANNALS OF ONCOLOGY (2010)
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Meng-Lei Zhu et al.
CANCER RESEARCH (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
Alain C. Mita et al.
CLINICAL CANCER RESEARCH (2009)
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase 3, Randomized, Controlled Trial of Atrasentan in Patients With Nonmetastatic, Hormone-Refractory Prostate Cancer
Joel B. Nelson et al.
CANCER (2008)
Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer
Jean-Pascal Machiels et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III Trial of Androgen Ablation With or Without Three Cycles of Systemic Chemotherapy for Advanced Prostate Cancer
Randall E. Millikan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers
Stephane Culine et al.
JOURNAL OF UROLOGY (2007)
Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: A phase II study
R. Lord et al.
JOURNAL OF UROLOGY (2007)
Limited tissue penetration of taxanes: A mechanism for resistance in solid tumors
Alastair H. Kyle et al.
CLINICAL CANCER RESEARCH (2007)
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A southwest oncology group trial S0111
M Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer
AW Tolcher et al.
CLINICAL CANCER RESEARCH (2005)
Microtubules as a target for anticancer drugs
MA Jordan et al.
NATURE REVIEWS CANCER (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
LM Glode et al.
CANCER (2003)
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate
CN Papandreou et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies
K Kawai et al.
CANCER LETTERS (2000)
分享论文
